Key result
In young spontaneously hypertensive rats, ramipril increased renal medullary neutral lipids compared with controls (0.99% vs 0.56%, P<0.01) and reduced blood pressure at 10 weeks of age.
Why the study?
Does ramipril increase renal medullary neutral lipids and reduce blood pressure in young spontaneously hypertensive rats?
Does ramipril increase renal medullary neutral lipids and reduce blood pressure in young spontaneously hypertensive rats?
Absolute Event Rate: 0.99% vs 0.56%
p-value: p=<0.01
ACE inhibition with ramipril increases renal medullary neutral lipids and reduces blood pressure in spontaneously hypertensive rats, an effect that appears to depend on bradykinin.
Hypothesis-generating in hypertensive rat models; leaves open any translation to human hypertension therapy.
Short-term treatment of young spontaneously hypertensive rats (SHR) with angiotensin-converting enzyme (ACE) inhibitors reduces systolic blood pressure. Renal medullary neutral lipids (RMNLs) have vasodilator properties that may explain the effects of ACE inhibition. We measured RMNL levels of SHR treated between 6 and 10 weeks of age with (1) vehicle, (2) ramipril 1 mg. kg-1. d-1, (3) the bradykinin B2 receptor antagonist icatibant 0.5 mg. kg-1. d-1, or (4) icatibant 0.5 mg. kg-1. d-1 plus ramipril 1 mg. kg-1. d-1. RMNLs were quantified by oil red O fluorescence at 10 and 20 weeks of age. Systolic blood pressure (BP) was measured by tail-cuff plethysmography. Ramipril reduced BP at 10 weeks of age and increased RMNLs compared with controls (0.99+/-0.07% versus 0.56+/-0. 06%, P<0.01). Icatibant alone had no significant effect on RMNLs (0.55+/-0.04%) but attenuated the increase in RMNLs by ramipril (0. 81+/-0.05%). In control SHR, the increase in BP between 10 and 20 weeks of age was associated with a significant increase in RMNLs (0.79+/-0.09%). SHR that had received ramipril had significantly lower BP than controls at 20 weeks of age, but RMNL was not significantly different (0.92+/-0.10%). Therefore, in young SHR, ACE inhibition increases RMNLs and reduces blood pressure, an effect that appears to depend on bradykinin. The changes in RMNLs at the age of 10 weeks paralleled long-term BP effects and may be involved in setting the BP track in SHR.
No takes yet. Share an insight, caveat, or question.
O’Sullivan et al. (1999) studied Hypertension. Ramipril vs. Vehicle was evaluated on Renal medullary neutral lipids (RMNLs) at 10 weeks of age (p=<0.01). In young spontaneously hypertensive rats, ramipril increased renal medullary neutral lipids compared with controls (0.99% vs 0.56%, P<0.01) and reduced blood pressure at 10 weeks of age.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: